Prophylaxis against Neisseria meningitidis infections and antibody responses in patients with deficiency of the sixth component of complement

The Journal of Infectious Diseases
P C PotterA Orren

Abstract

Forty South African patients with homozygous deficiency of the sixth component of complement (C6) have been identified in an area where group B meningococcal meningitis is endemic; 22 of the 24 proband cases presented with recurrent meningococcal meningitis. In a 2- to 4-year prospective study, patients with recurrent infections who received monthly prophylactic long-acting penicillin were significantly protected from subsequent neisserial infection compared with those who did not receive penicillin (P = .02, Fisher's exact test). Heterogeneous susceptibility to neisserial infection was confirmed by following C6-deficient patients who presented with one or no Neisseria meningitidis infections. These patients, on no prophylaxis, had significantly fewer infections (P = .004) than did patients who presented with recurrent disease. Functional C6 activity was restored by transfusion of fresh frozen plasma in a C6-deficient patient resistant to conventional antibiotic treatment. Antibody levels to the serotype 2 outer membrane proteins were significantly elevated in C6-deficient patients compared with control groups (P = .001).

Citations

Jan 1, 1993·Immunologic Research·J FigueroaP Densen
Mar 23, 2005·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A FraserL Leibovici
Aug 27, 2004·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Michael CorviniSteven I Aronin
Dec 1, 1996·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·G RyuM C Zacharisen
Dec 9, 1998·Clinical and Experimental Immunology·B P Morgan, A Orren
Dec 9, 1998·Clinical and Experimental Immunology·A M O'HaraM J Hobart
Jan 13, 2000·Clinical and Experimental Immunology·M Drogari-ApiranthitouE J Kuijper
Jun 1, 1993·Scandinavian Journal of Immunology·R BiselliM Brai
Jul 16, 2008·Clinical Microbiology Reviews·Marc Tebruegge, Nigel Curtis
Oct 12, 2010·Clinical Microbiology Reviews·Sanjay RamPeter A Rice
Sep 9, 2006·Journal of the Formosan Medical Association = Taiwan Yi Zhi·Yi-Chi ChiangPei-Hsuan Liang
Feb 26, 2014·The Journal of Allergy and Clinical Immunology. in Practice·Merin Kuruvilla, Maria Teresa de la Morena
Aug 1, 1992·Clinical Immunology and Immunopathology·A E PlatonovL V Serebrovskaya
Oct 10, 2013·Virulence·Lisa A Lewis, Sanjay Ram
Apr 24, 2009·Vaccine·Francesco Tedesco
Apr 29, 2011·BMC Public Health·Debajeet ChoudhuriIgor Rudan
Dec 24, 2014·Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie·C de MarcellusT Guiddir
Sep 1, 1991·Immunology Today·B P Morgan, M J Walport
Mar 18, 2015·Clinical Pediatrics·Vivian P Hernandez-TrujilloJordan S Orange
Jul 13, 2002·American Journal of Medical Genetics·Doron BeharHanna Mandel
Apr 16, 2005·Journal of Korean Medical Science·Chang-Seok KiWon-Duck Kim
Feb 1, 1993·Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology·B Z GartyY L Danon
Nov 1, 1993·Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology·M B FasanoJ A Winkelstein
Oct 29, 2013·The Cochrane Database of Systematic Reviews·Anca Zalmanovici TrestioreanuLeonard Leibovici
Jul 1, 1991·Clinical Microbiology Reviews·J E Figueroa, P Densen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.